Reinach, Switzerland, 24 September 2013 – The US Defense Threat Reduction Agency (DTRA) has announced that it has selected Evolva to enter into contract negotiations regarding possible preclinical funding for Evolva’s antibiotic compound GC-072 (the lead compound in Evolva’s EV-035 series) under the Transformational Medical Technologies Initiative (TMTI). The size of the award could be up to USD 14.7 million.
GC-072 is a broad-spectrum antibiotic that has demonstrated utility in preclinical studies in vitro and in vivo against a wide range of bacterial pathogens, most notably Burkholderia pseudomallei. This bacterium causes the disease melioidosis, and is regarded as a potential biothreat agent.
The contract negotiations are expected to take several months to complete. There is no guarantee of a successful outcome. If successful, Evolva will provide an update that explains the publicly available parameters of this DTRA award in greater detail.
Evolva continues to pursue options to partner its pharmaceutical pipeline in line with its strategy of focusing on high value ingredients for health, wellness and nutrition.
– Ends –